Dr. Reddy’s Laboratories (RDY) Set to Announce Earnings on Tuesday

Dr. Reddy’s Laboratories (NYSE:RDY) is scheduled to be announcing its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.86 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $75.21 on Monday. The business’s fifty day moving average is $73.97 and its 200 day moving average is $70.75. Dr. Reddy’s Laboratories has a 12-month low of $53.12 and a 12-month high of $77.72. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The stock has a market cap of $12.55 billion, a P/E ratio of 19.84, a P/E/G ratio of 1.88 and a beta of 0.57.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RDY shares. Barclays boosted their price target on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Finally, Jefferies Financial Group downgraded Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $80.00.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.